Literature DB >> 22530956

Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population-based study.

A Schiopu1, B Hedblad, G Engström, J Struck, N G Morgenthaler, O Melander.   

Abstract

OBJECTIVES: A number of inflammatory biomarkers such as C-reactive protein (CRP) are independent predictors of cardiovascular risk. The inflammatory biomarker procalcitonin (PCT) has previously been shown to be associated with coronary atherosclerosis and the metabolic syndrome. We evaluated the ability of PCT to predict future cardiovascular events in a population of apparently healthy individuals.
DESIGN: We measured plasma PCT levels in 3713 subjects with no previous history of cardiovascular disease, randomly selected from the Malmö Diet and Cancer cohort. The correlation between PCT concentration and the incidence of coronary events, stroke and cardiovascular death over a median follow-up period of 13.7 years was studied using a Cox regression analysis corrected for age, sex, CRP level, traditional risk factors and renal function.
RESULTS: Age and sex were strong determinants of PCT; the concentration of PCT was significantly higher in men than in women. PCT was associated with several of the established cardiovascular risk factors (CRP, hypertension, diabetes and renal function) as determined by multivariate linear regression. Of note, PCT was inversely correlated with HDL and smoking. We found significant correlations between PCT levels, coronary events and cardiovascular death. However, these relationships lost statistical significance when the analysis was corrected for CRP and the traditional risk factors.
CONCLUSIONS: This is the largest population-based prospective study to demonstrate a positive association between plasma PCT levels and cardiovascular risk in subjects with no previous history of acute cardiovascular events. However, the high degree of covariation between PCT and other cardiovascular risk factors limits the value of PCT as an independent cardiovascular risk predictor.
© 2012 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22530956     DOI: 10.1111/j.1365-2796.2012.02548.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  14 in total

1.  Procalcitonin and Pentraxin-3: Current biomarkers in inflammation in white coat hypertension.

Authors:  H Yavuzer; M Cengiz; S Yavuzer; M Rıza Altıparmak; B Korkmazer; H Balci; A L Yaldıran; H Uzun
Journal:  J Hum Hypertens       Date:  2015-06-04       Impact factor: 3.012

2.  Predictive value of preprocedural procalcitonin for short- and long-term mortality after transfemoral transcatheter aortic valve implantation.

Authors:  Stanislav Keranov; Won-Keun Kim; Mani Arsalan; Matthias Renker; Till Keller; Timm Bauer; Oliver Dörr; Holger M Nef; Luise Gaede; Helge Möllmann; Thomas Walther; Christian W Hamm; Christoph Liebetrau
Journal:  Heart Vessels       Date:  2019-06-07       Impact factor: 2.037

3.  Relationship between procalcitonin serum levels and functional outcome in stroke patients.

Authors:  Wen-Jing Deng; Rui-Le Shen; Meng Li; Jun-Fang Teng
Journal:  Cell Mol Neurobiol       Date:  2014-11-05       Impact factor: 5.046

4.  Procalcitonin Is a Stronger Predictor of Long-Term Functional Outcome and Mortality than High-Sensitivity C-Reactive Protein in Patients with Ischemic Stroke.

Authors:  Chao Wang; Li Gao; Zhi-Guo Zhang; Yu-Qian Li; Yan-Long Yang; Tao Chang; Long-Long Zheng; Xing-Ye Zhang; Ming-Hao Man; Li-Hong Li
Journal:  Mol Neurobiol       Date:  2015-02-04       Impact factor: 5.590

5.  Procalcitonin and Midregional Proatrial Natriuretic Peptide as Markers of Ischemic Stroke: The Northern Manhattan Study.

Authors:  Mira Katan; Yeseon P Moon; Myunghee C Paik; Beat Mueller; Andreas Huber; Ralph L Sacco; Mitchell S V Elkind
Journal:  Stroke       Date:  2016-05-19       Impact factor: 7.914

6.  Carotid intima media thickness and blood biomarkers of atherosclerosis in patients after stroke or myocardial infarction.

Authors:  Iwona Kurkowska-Jastrzebska; Michał A Karlinski; Beata Błazejewska-Hyzorek; Iwona Sarzynska-Dlugosz; Krzysztof J Filipiak; Anna Czlonkowska
Journal:  Croat Med J       Date:  2016-12-31       Impact factor: 1.351

Review 7.  Emerging families of biomarkers for coronary artery disease: inflammatory mediators.

Authors:  Josef Yayan
Journal:  Vasc Health Risk Manag       Date:  2013-07-31

8.  Procalcitonin beyond the acute phase: novel biomediator properties?

Authors:  Carolina Panico; Eric Nylen
Journal:  BMC Med       Date:  2013-08-28       Impact factor: 8.775

9.  Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study.

Authors:  Ovidiu S Cotoi; Jonas Manjer; Bo Hedblad; Gunnar Engström; Olle Melander; Alexandru Schiopu
Journal:  BMC Med       Date:  2013-08-13       Impact factor: 8.775

10.  Elevated serum tartrate-resistant acid phosphatase isoform 5a levels in metabolic syndrome.

Authors:  Yi-Jhih Huang; Tsai-Wang Huang; Tsu-Yi Chao; Yu-Shan Sun; Shyi-Jou Chen; Der-Ming Chu; Wei-Liang Chen; Li-Wei Wu
Journal:  Oncotarget       Date:  2017-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.